Skip to main content
    C

    Cidara Therapeutics Inc (CDTX)

    Official site

    BIOTECHNOLOGY

    $221.38
    +0.00 (+0.00%)

    Last updated: Jan 07, 2026 at 4:00 PM ET

    Cidara Therapeutics Inc (CDTX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 6, 2025. Financial statements from company filings, amounts in US dollars.

    Cidara Therapeutics reported revenue of $1.27M for the fiscal year ended Dec 31, 2024, down 94.5% from the year before. That year, net income was -$169.83M with a net margin of -13319.8%, operating cash flow was -$176.53M and free cash flow was -$176.66M. The quarter ended Sep 30, 2025 had revenue of $0 and net income of -$83.23M.

    Revenue and Margins

    Over the 5 years to Dec 2024, revenue fell from $20.91M, a compound annual decline of 42.9%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2024$1.27M-94.5%100.0%-13811.9%-13319.8%
    Dec 2023$23.28M-63.9%100.0%-116.2%-98.5%
    Dec 2022$64.45M+30.0%100.0%-52.0%-52.1%
    Dec 2021$49.57M+310.8%100.0%-85.2%-85.7%
    Dec 2020$12.07M-42.3%100.0%-595.4%-597.6%
    Dec 2019$20.91MN/A100.0%-199.5%-196.5%
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Dec 2015$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2015 to Dec 2024

    Income Statement

    In the fiscal year ended Dec 2024, the net loss widened from the year before. In the quarter ended Sep 2025, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015
    Revenue$1.27M$23.28M$64.45M$49.57M$12.07M$20.91M$0$0$0$0
    Gross profit$1.27M$23.28M$64.45M$49.57M$12.07M$20.91M$0$0$0$0
    Research and development$156.76M$36.76M$77.41M$73.09M$68.02M$46.40M$49.14M$42.82M$35.70M$23.48M
    Operating income-$176.10M-$27.06M-$33.50M-$42.26M-$71.85M-$41.72M-$63.28M-$55.72M-$48.44M-$32.31M
    Net income-$169.83M-$22.93M-$33.58M-$42.47M-$72.11M-$41.09M-$59.02M-$55.73M-$48.16M-$32.19M
    EBITDA-$175.69M-$26.86M-$33.17MN/A-$70.79M-$40.98M-$59.08M-$55.04M-$47.88M-$31.87M
    Fiscal years ended Dec 2015 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Revenue$0$0$0-$7.49M$0$302.00K$973.00K-$17.13M$9.22M$5.09M$26.11M$10.38M
    Gross profit$0$0$0-$7.49M$0$302.00K$973.00K-$17.13M$9.22M$5.09M$26.11M$10.38M
    Operating income-$88.63M-$27.38M-$25.27M-$52.03M-$17.39M-$95.98M-$8.54M-$18.63M-$4.47M-$6.75M$2.78M-$17.05M
    Net income-$83.23M-$25.72M-$23.48M-$52.31M-$15.98M-$91.21M-$10.33M-$3.21M-$9.11M-$13.62M$3.01M-$17.16M
    Last 12 quarters

    Balance Sheet

    As of Dec 2024, cash and equivalents exceeded short-term debt of $1.64M by $188.18M.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015
    Total assets$214.80M$67.03M$47.49M$75.33M$60.42M$68.98M$79.11M$79.03M$106.96M$109.97M
    Current assets$210.74M$60.85M$45.09M$71.70M$57.19M$65.81M$77.13M$77.67M$105.40M$108.22M
    Cash and equivalents$189.82M$35.78M$32.73M$59.68M$35.91M$50.27M$74.56M$60.81M$85.37M$62.56M
    Total liabilities$51.49M$75.24M$61.92M$53.75M$49.71M$31.14M$19.97M$19.29M$18.78M$6.06M
    Short-term debt$1.64M$1.30M$1.21M$2.59M$7.02M$9.96M$9.93M$2.67M$0N/A
    Long-term debtN/AN/AN/AN/AN/AN/AN/A$7.21M$9.79M$0
    Shareholder equity$163.31M-$8.21M-$14.44M$21.57M$10.71M$37.84M$59.14M$59.74M$88.18M$103.91M
    Fiscal years ended Dec 2015 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Total assets$518.65M$534.33M$191.73M$214.80M$162.33M$173.36M$52.72M$67.03M$63.47M$67.99M$81.74M$47.49M
    Total liabilities$96.26M$33.15M$50.05M$51.49M$46.70M$42.42M$70.50M$75.24M$55.43M$52.57M$54.90M$61.92M
    Cash and equivalents$293.65M$510.57M$168.15M$189.82M$127.39M$164.37M$29.02M$35.78M$48.67M$50.43M$47.98M$32.73M
    Shareholder equity$422.39M$501.17M$141.68M$163.31M$115.63M$130.94M-$17.78M-$8.21M$8.04M$15.41M$26.84M-$14.44M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2024.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015
    Operating cash flow-$176.53M-$22.43M-$28.47M-$25.23M-$54.41M-$28.53M-$56.70M-$49.91M-$39.77M-$25.96M
    Capital expenditures$129.00K$505.00K$118.00K$41.00K$186.00K$35.00K$177.00K$306.00K$401.00K$1.17M
    Free cash flow-$176.66M-$22.94M-$28.59M-$25.27M-$54.60M-$28.57M-$56.88M-$50.22M-$40.17M-$27.13M
    Share repurchasesN/AN/A$720.00K$0$0$31.00K$0$79.00K$0$0
    Investing cash flow-$129.00K-$505.00K-$118.00K-$41.00K-$186.00K-$35.00K$14.30M$4.47M$25.48M-$46.09M
    Financing cash flow$337.06M$25.98M-$951.00K$44.60M$37.28M$14.27M$56.15M$20.88M$37.09M$111.81M
    Fiscal years ended Dec 2015 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Operating cash flow-$40.62M-$40.96M-$21.95M-$29.41M-$36.70M-$103.78M-$6.64M-$12.72M-$1.63M$2.82M-$10.90M-$21.00M
    Capital expenditures$0$0$0$0$106.00K$0$23.00K$178.00K$126.00K$107.00K$94.00K$9.00K
    Free cash flow-$40.62M-$40.96M-$21.95M-$29.41M-$36.80M-$103.78M-$6.67M-$12.90M-$1.76M$2.71M-$10.99M-$21.01M
    Last 12 quarters

    Frequently Asked Questions About CDTX

    What is Cidara Therapeutics' annual revenue?

    Cidara Therapeutics reported revenue of $1.27M for the fiscal year ended Dec 31, 2024.

    How fast is Cidara Therapeutics' revenue growing?

    Revenue was down 94.5% for the fiscal year ended Dec 31, 2024 compared with the year before. The compound annual revenue growth rate over 3 years was -70.5%.

    Is Cidara Therapeutics profitable?

    No. Cidara Therapeutics reported net income of -$169.83M for the fiscal year ended Dec 31, 2024, with a net margin of -13319.8%.

    How much free cash flow does CDTX generate?

    For the fiscal year ended Dec 31, 2024, operating cash flow of -$176.53M minus capital expenditures of $129.00K produced free cash flow of -$176.66M.

    How much debt does Cidara Therapeutics have?

    The balance sheet dated Dec 31, 2024 reported short-term debt of $1.64M and cash and equivalents of $189.82M.